WARRINGTON, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage ...

WARRINGTON, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for ...

Diabetic cardiomyopathy (DCM) is a progressive complication associated with type 2 diabetes (T2D), causing deterioration of cardiac function in diabetic patients, independent of coronary artery ...

Collaboration to focus on the continued development of chronic heart failure treatment SERCA2a activator compounds adding to Windtree's acute treatment Istaroxime WARRINGTON, Pa., March 22, 2021 ...

Gene transfer of SERCA2a improves contractility and myocardial energetics in the setting of heart failure Overexpression of SERCA2a has antiproliferative and vasodilatory effects on the vasculature ...

Arrhythmias are irregular heartbeats that can impact the pumping function of the heart. Patients with heart failure and cardiomyopathy are at risk for arrhythmias. Arrhythmias in these patients can be ...

Windtree Therapeutics, Inc. announced progress in its research on istaroxime and a selective SERCA2a activator, demonstrating a reduction in arrhythmias in an animal study, which will be presented at ...

Boston, MA - The improvement of intracellular calcium cycling, through overexpression of the sarcoplasmic reticulum CA 2+ ATPase pump (SERCA2a), reduces arrhythmias and restores contractile function ...

An intersegmental single-cell profile reveals aortic heterogeneity and identifies a novel Malat1 + vascular smooth muscle subtype involved in abdominal aortic aneurysm formation A difference between ...

Diabetic cardiomyopathy (DCM) is a progressive complication associated with type 2 diabetes (T2D), causing deterioration of cardiac function in diabetic patients, independent of coronary artery ...